Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Results: Thirteen patients received a ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
Credit: Getty Images. 5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. Use of 5α-reductase inhibitors (5-ARIs) prior to a bladder ...
Bladder Pain Syndrome is believed to arise from bladder wall hypersensitivity and disruption of its protective lining, ...
Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...
5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH). Use of 5α-reductase inhibitors (5-ARIs) prior to a bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results